期刊文献+

伪膜性肠炎诊疗进展 被引量:1

Progress in diagnosis and treatment of pseudomembranous colitis
原文传递
导出
摘要 伪膜性肠炎的发生与抗生素的使用密切相关,其致病菌约100%为艰难梭菌.诊断主要是在临床表现的基础上通过粪便培养、毒素检测、结肠镜检查和(或)组织学检查.一旦确诊或高度怀疑本病,应立即停用原有抗生素,以甲硝唑和(或)万古霉素抗感染治疗,并辅以益生菌及营养支持治疗.近年来,仍出现新型的治疗方案.该文对伪膜性肠炎的相关情况进行阐述,以提高临床医生对其的认识. Pseudomembranous colitis occurred is closely related to the use of antibiotics and the pathogenic bacteria approximately 100% is clostridium difficile.Diagnosis is mainly based on clinical manifestations,stool culture,toxin detection,colonoscopy and/or histological examination.Once the diagnosis has been confirmed or highly suspected,the initial antibiotic therapy should be discontinued,add with metronidazole and/or vancomycin,supplement by probiotic and nutritional support.The recent years,new treatment options have been proposed.This article presents an review of the related situation of pseudomembranous colitis to improve the comprehension for clinical doctors.
出处 《国际儿科学杂志》 2015年第2期146-148,共3页 International Journal of Pediatrics
关键词 伪膜性肠炎 艰难梭菌 诊断 治疗 Pseudomembranous colitis Clostridium difficile Diagnosis Treatment
  • 相关文献

参考文献24

  • 1Bartlett JG,Chang T,Taylor NS ,et al. Colitis induced by Clostridium difficile[J].Rev Infect Dis, 1979,1 (2) :370-378.
  • 2He M,Miyajima F,Roberts P,et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile [J]. Nat Genet, 2013,45 ( 1 ) :109-113.
  • 3Gerding DN. Clostridium difficile infection prevention: biotherapeu- tics,immunologics, and vaccines [ J ]. Discov Med,2012,13 (68) :75- 83.
  • 4Louie TJ,Miller MA,Mullane KM, et al Fidaxomicin versus vanco- mycin for Clostridium difficile infection [J]. N Engl J Med, 2011, 364(5) :422-431.
  • 5Dial S, Kezouh A, Dascal A, et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection [ J ]. CMAJ,2008,179(8) :767-772.
  • 6Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile [ J ]. Clin Microbiol Infect, 2001,7 ( 8 ) : 421-427.
  • 7Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC)among Clostridium difficile clinical isolates [J]. J Clin Microbiol, 2002,40 ( 9 ) : 3470-3475.
  • 8Owens RC. Clostridium difficile-associated disease:changing epide- miology and implications for management [ J ]. Drugs, 2007,67 ( 4 ) : 487 -502.
  • 9Simor AE. Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities : a review [ J ]. J Am Geriatr Soc ,2010,58 ( 8 ) : 1556-1564.
  • 10Popoff MR, Rubin EJ, Gill DM, et ai. Actin-specific ADP-ribosyl- transferase produced by a Clostridium difficile strain [ J ]. Infect Im- mun,1988,56 (9) :2299-2306.

二级参考文献2

共引文献18

同被引文献3

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部